ストックスクリーナーアプリを入手
2.29
0.00%
0.00
アフターアワーズ：
2.32
0.03
+1.31%
前日終値:
$2.29
開ける：
$2.32
24時間の取引高:
29,571
Relative Volume:
0.25
時価総額：
$36.76M
収益：
$3.86M
当期純損益:
$-19.20M
株価収益率:
-3.1465
EPS:
-0.7278
ネットキャッシュフロー:
$-24.88M
1週間 パフォーマンス:
-0.43%
1か月 パフォーマンス:
-11.58%
6か月 パフォーマンス:
-36.21%
1年 パフォーマンス:
-55.75%
1日の値動き範囲:
$2.265
$2.35
1週間の範囲:
$2.2054
$2.39
52週間の値動き範囲:
$2.10
$7.40
Veru Inc Stock (VERU) Company Profile
Compare VERU vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.29 | 36.76M | 3.86M | -19.20M | -24.88M | -0.7278 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-14 | 開始されました | B. Riley Securities | Buy |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2023-06-07 | アップグレード | Jefferies | Underperform → Hold |
| 2021-04-13 | 開始されました | Jefferies | Buy |
| 2021-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2018-07-03 | 開始されました | Maxim Group | Buy |
すべてを表示
Veru Inc (VERU) 最新ニュース
Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment - MSN
If You Invested $1,000 in Veru (VERU) - Stock Titan
Volume Recap: Is Veru Inc attractive for institutional investors2026 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Veru Inc. Amends 2018 Equity Incentive Plan and Reports Annual Meeting Results – Form 8-K Filing March 12, 2026 - Minichart
Veru Shareholders Expand Equity Plan, Reelect Board Leadership - The Globe and Mail
Veru (NASDAQ: VERU) investors back larger equity plan, board slate and auditor - Stock Titan
Aug Macro: Is Veru Inc attractive for institutional investors2026 Opening Moves & Daily Market Momentum Tracking - baoquankhu1.vn
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study - TipRanks
Veru enrolls first patient in obesity drug combination trial By Investing.com - Investing.com Canada
Veru (VERU) Launches Phase 2b Trial for Obesity Treatment - GuruFocus
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TipRanks
Veru enrolls first patient in obesity drug combination trial - Investing.com Australia
Veru Inc. Initiates Phase 2b Clinical Trial for Enobosarm to Enhance Weight Loss in Older Patients with Obesity Receiving Semaglutide - Quiver Quantitative
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Yahoo Finance
VERU Earnings History & Surprises | EPS & Revenue Results | VERU INC (NASDAQ:VERU) - ChartMill
Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Veru : Corporate Presentation, February 2026 - marketscreener.com
VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VERU Should I Buy - Intellectia AI
Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com
VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI
Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI
Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Q1 2026 earnings preview - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru (VERU) price target increased by 11.11% to 25.50 - MSN
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru Inc (VERU) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):